Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
Expert Rev Vaccines
; 12(4): 379-93, 2013 Apr.
Article
em En
| MEDLINE
| ID: mdl-23560919
ABSTRACT
Replication-defective chimpanzee adenovirus vectors are emerging as a promising new class of genetic vaccine carriers. Chimpanzee adenovirus vectors have now reached the clinical stage and appear to be endowed with all the properties needed for human vaccine development, including high quality and magnitude of the immune response induced against the encoded antigens, good safety and ease of manufacturing on a large-scale basis. Here the authors review the recent findings of this novel class of adenovirus vectors and compare their properties to other clinical stage vaccine vectors derived from poxvirus, alphavirus and human adenovirus.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Portadores de Fármacos
/
Adenovirus dos Símios
/
Vacinação
/
Sistemas de Liberação de Medicamentos
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article